Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ; Prevention of Renal and Vascular End Stage Disease Study Group. Boersma C, et al. Clin Ther. 2010 Jun;32(6):1103-21. doi: 10.1016/j.clinthera.2010.06.013. Clin Ther. 2010. PMID: 20637965 Free article.
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ; PREVEND IT Study Group. Atthobari J, et al. Clin Ther. 2006 Mar;28(3):432-44. doi: 10.1016/j.clinthera.2006.03.012. Clin Ther. 2006. PMID: 16750458
The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention.
Özyilmaz A, Boersma C, Visser ST, Postma MJ, de Jong-van den Berg LT, Lambers-Heerspink HJ, de Jong PE, Gansevoort RT. Özyilmaz A, et al. Among authors: de jong van den berg lt. Eur J Prev Cardiol. 2016 May;23(8):847-55. doi: 10.1177/2047487315604310. Epub 2015 Sep 10. Eur J Prev Cardiol. 2016. PMID: 26358992
279 results